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Introduction {#sec1}
============

Amyotrophic lateral sclerosis (ALS) is characterized by the progressive loss of upper and lower motor neurons. The loss of these neurons leads to the concomitant development of skeletal muscle atrophy ([@bib45]). ALS is a disease of obscure etiology, for which neither a cure nor a therapeutic option is available. ALS is a multifactorial disease and a number of mechanisms have been proposed to underpin disease pathology, including alterations in RNA metabolism, oxidative stress, axonal transport defects, neuroinflammation, impaired protein homeostasis, alterations in autophagic flux, aberrant cytoplasmic-nuclear shuttling, failure in DNA repair, excitotoxicity, mitochondrial dysfunction, and vesicular transport defects ([@bib34]).

In spite of its elusive etiology, some well-described clinical signs in patients with ALS highlight promising lines of investigation to improve our understanding of disease. Notably, hypermetabolism ([@bib50]) and weight loss ([@bib36]) are associated with worse prognosis. However, weight loss, undernutrition, muscle atrophy, weakness, and reduced physical activity ([@bib26]) appear incompatible with clinical studies reporting increased energy expenditure (EE) in patients with ALS ([@bib6], [@bib9], [@bib16], [@bib28]). The paradox may be reconciled by assuming that skeletal muscle plays a pathological role in ALS, contributing to defective energy metabolism and a derangement of basal metabolic rate. Indeed, skeletal muscle is a key determinant of whole-body metabolic rate ([@bib58]).

In this context, the early events underlying defective muscle metabolism in ALS as well as the major molecular mechanisms that cause ALS-associated hypermetabolism are still unknown. We therefore undertook this investigation to provide insights into the early pathological events involved in ALS by examining the mechanisms responsible for maladaptive muscle oxidative metabolism and disease progression. Finally, in this study, we provided evidences to show that pharmacological modulation of metabolism can curtail excessive EE and improve ALS pathology, thereby demonstrating that limiting hypermetabolism could be a promising therapeutic target in ALS.

Results {#sec2}
=======

An Increase in Fatty Acid Oxidation and Glucose Intolerance Precedes Hypermetabolism in SOD1^G93A^ Mice {#sec2.1}
-------------------------------------------------------------------------------------------------------

To investigate the whole-body metabolic status and fuel oxidation in SOD1^G93A^ mice, we conducted indirect calorimetry over 2 or 3 continuous days. Measures were obtained from animals at the early presymptomatic (55 days of age) and symptomatic (120 days of age) stages of disease. Hypermetabolism, defined as an increase in total EE or resting energy expenditure (REE), was not detectable in early presymptomatic mice ([Figures 1](#fig1){ref-type="fig"}A--1C) but was strongly evident in symptomatic mice ([Figures 1](#fig1){ref-type="fig"}D--1F). Analysis of the respiratory exchange ratio (RER) revealed a significant genotype effect, with RER being reduced in both early presymptomatic and symptomatic SOD1^G93A^ mice when compared with wild-type control mice ([Figures 1](#fig1){ref-type="fig"}G and 1H). These results are indicative of enhanced fatty acid oxidation and predominant use of fatty acids as fuel source in ALS mice.Figure 1Energy Expenditure and Metabolic Profile of WT and SOD1^G93A^ Mice(A--L) (A) Energy expenditure profiles of early presymptomatic SOD1^G93A^ mice (55 days) and their wild-type control littermates (WT). Black bar indicates dark cycle period. Mean (B) energy expenditure (EE) and (C) resting energy expenditure (REE) calculated from (A). (D) Energy expenditure profiles of symptomatic SOD1^G93A^ mice (120 days) and their wild-type control littermates (WT). Mean (E) EE and (F) REE calculated from (D). (G and H) Mean RER from (A) and (D), respectively. (I) Gene expression changes in the tibialis anterior (TA) muscle from SOD1^G93A^ mice and their wild-type control littermates. (J) Heatmap depicting expression of genes from the Reactome category "Glycolysis." Shown genes are differentially expressed with adjusted p \< 0.05. (K) Network plot of the \"Pyruvate metabolism and Citric Acid (TCA) cycle\" pathways. Nodes are genes colored based on log2FC, edges are knowledge-based interactions annotated by Reactome. (L) Glucose tolerance test performed in SOD1^G93A^ and in their wild-type control littermates (WT) at 55, 90, and 120 days of age, respectively. Data in (B), (C), (E), (F), (G), and (H) are presented as mean ± SEM, ∗∗∗p \< 0.0001, unpaired Student\'s t test.

After confirmed metabolic alteration in presymptomatic SOD1^G93A^ mice and since skeletal muscle is the major factor affecting EE also at rest ([@bib58]) we carried out RNA sequencing to assay gene expression changes in the *tibialis anterior* (TA) of SOD1^G93A^ mice at the onset stage of disease, when compared with their wild-type littermate controls. Gene enrichment analysis, using Reactome categories, highlighted that the gene sets most significantly enriched among downregulated genes were associated with glucose metabolism ([Figure 1](#fig1){ref-type="fig"}I). In particular, we observed downregulation of key glycolysis pathway genes ([Figures 1](#fig1){ref-type="fig"}J and 1K). The decrease in the expression of glycolytic pathway genes was further supported through our assessment of glucose tolerance in SOD1^G93A^ mice. At the early presymptomatic stage, SOD1^G93A^ mice already show a marked decrease in blood glucose clearance with respect to wild-type control littermates ([Figure 1](#fig1){ref-type="fig"}L, upper panel). This metabolic alteration dramatically worsened with disease progression in SOD1^G93A^ mice ([Figure 1](#fig1){ref-type="fig"}L, middle and lower panels).

ALS Skeletal Muscles Undergo Metabolic Reprogramming {#sec2.2}
----------------------------------------------------

Based on results obtained through indirect calorimetry and transcriptome analysis, we aimed to define the timing of the onset of metabolic changes in skeletal muscle of SOD1^G93A^ mice by analyzing the oxidative capacity of the glycolytic TA at different time points. We found that *in situ* NADH-TR and SDH activities were dramatically increased in SOD1^G93A^ mice at the early presymptomatic stage (55 days) and to a higher degree at the later stages of the disease ([Figures 2](#fig2){ref-type="fig"}A, 2B, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B).Figure 2Muscle Metabolism Switches from Glycolytic to Oxidative in SOD1^G93A^ Mice(A) Representative NADH-tetrazolium reductase activity staining on tibialis anterior (TA) cross sections obtained from 55-, 90-, and 150-day-old SOD1^G93A^ mice and their wild-type control littermates (WT). Scale bar, 100 μm, *n* = 3.(B) Representative SDH activity staining on TA cross sections of 55-, 70-, 90-, and 120-day-old SOD1^G93A^ mice and their wild-type control littermates (WT). The darker color indicates the site of SDH activity. Scale bar, 100 μm, *n* = 3.(C--E) (C) Representative images of TA sections from 55-, 90-, and 150-day-old SOD1^G93A^ and wild-type (WT) mice, immunostained with laminin (green) and the mitochondrial marker ATPB (red); nuclei were detected with Hoechst 33342 (blue). Scale bar, 100 μm, *n* = 3. Expression level of mRNAs coding for (D) Nor1 and Myoglobin and (E) MyHCI, MyHCIIa, MyHCIIIx, and MyHCIIb in TA sections obtained from SOD1^G93A^ at the indicated ages (at least *n* = 4). Data are presented as mean ± SEM, ∗p \< 0.05, ∗∗p \< 0.001, ∗∗∗p \< 0.0001, compared with wild-type control littermates at the same age (arbitrarily set at 1), unpaired Student\'s t test.Also see [Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C.

In line with the rise in muscle oxidative capacity, we detected, by immunofluorescence analysis, a consistent increase in the intensity of ATPB, a known mitochondrial marker, in the TA muscle of SOD1^G93A^ mice ([Figures 2](#fig2){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). Accordingly, a striking increase in mitochondrial mass was observed, defined by an increase in the amount (μg) of mitochondria per milligram of tissue as well as an increase in the content of mitochondrial DNA, in different muscles of SOD1^G93A^ mice during the course of the disease ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). Interestingly, this phenomenon occurred mainly in glycolytic muscles and not in the oxidative *soleus* muscle.

The switching of skeletal muscle metabolism toward an oxidative phenotype in SOD1^G93A^ mice was further corroborated by the upregulation in neuron-derived orphan nuclear receptor (Nor1) mRNA in the TA ([Figure 2](#fig2){ref-type="fig"}D). This transcription factor is known to promote muscle remodeling toward oxidative metabolism by activating pathways critical for adaptation to exercise or energy deficit ([@bib19]). The upregulation of Nor1 in SOD1^G93A^ mice occurred alongside an upregulation in mRNA encoding for myoglobin ([Figure 2](#fig2){ref-type="fig"}D) ([@bib41]). Moreover, we found significant alterations in the expression of mRNAs encoding myosin heavy chain isoforms. Specifically, we observed a reduction in the expression of the glycolytic isoform MyCHIIb and an increase in the expression of the oxidative/intermediate isoforms MyHCIIa and MyHCIIx ([Figure 2](#fig2){ref-type="fig"}E). No significant alterations were observed in the expression of the oxidative isoform MyHCI ([Figure 2](#fig2){ref-type="fig"}E). Overall, these data show that, in SOD1^G93A^ mice, glycolytic muscles undergo a profound rearrangement in their physiology throughout the course of disease.

Mitochondrial Bioenergetics Are Perturbed in Skeletal Muscle of Early Presymptomatic SOD1^G93A^ Mice {#sec2.3}
----------------------------------------------------------------------------------------------------

The metabolic modifications of skeletal muscle observed in SOD1^G93A^ animals mirror adaptations to endurance training, wherein a switch from glycolytic to oxidative metabolism occurs ([@bib20], [@bib55]). During endurance training, this metabolic switch is accompanied by an increase in mitochondrial mass alongside significant remodeling of myofibers and a preferential use of fatty acids as fuel ([@bib20], [@bib55]). Although we found that mitochondrial mass in glycolytic TA muscle of SOD1^G93A^ mice increased during the disease course, we also noted an early mitochondrial bioenergetic defect. In this regard, we found that total ATP was significantly lower in the TA of SOD1^G93A^ mice at the early symptomatic through to the mid-stage of disease when compared with age-matched wild-type control mice ([Figure 3](#fig3){ref-type="fig"}A). Moreover, we observed a marked reduction in all mitochondrial functionalities in the TA of SOD1^G93A^ mice at the early presymptomatic phase of the disease. Similarly, early reductions in mitochondrial function were also observed in other glycolytic muscles, *gastrocnemius* (GNM) and *extensor digitorum longus* (EDL) ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Interestingly, bioenergetic defects only become detectable in the spinal cord at onset of the pathology ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}B).Figure 3Mitochondrial Bioenergetic Failure Occurs in Skeletal Muscle of Early Presymptomatic SOD1^G93A^ Mice(A) Fluorometric measurements of total ATP in the tibialis anterior (TA) muscle from SOD1^G93A^ and wild-type age-matched control mice (WT) at different ages. Data were analyzed by unpaired t test and presented as mean ± SEM, ∗∗∗p \< 0.0001 compared with age-matched WT mice (*n* = 4 independent experiments).(B) Coupling assay on isolated mitochondria purified from TA.(C) Spinal Cord of SOD1^G93A^ mice at the indicated ages. Mitochondrial respiration stages are reported as basal respiration (state 2), maximal coupled respiration (state 3), respiration due to proton leak (state 4o), and maximal uncoupled respiration (state 3u). Data are expressed as % Oxygen Consumption Rate (OCR), and 100% was arbitrarily assigned to values obtained from age-matched wild-type mice, ∗p \< 0.05, ∗∗p \< 0.001, ∗∗∗p \< 0.0001, unpaired Student\'s t test (*n* = 5 independent experiments).(D) Activity of electron transport chain complexes I, II\\III, and IV of mitochondria obtained from TA.(E) Spinal Cord of SOD1^G93A^ and wild-type (WT) mice at the indicated ages. Values were normalized to citrate synthase activity and presented as mean ± SEM, ∗∗p \< 0.001, ∗∗∗p \< 0.0001 compared with age-matched WT mice (arbitrarily set at 100%), unpaired Student\'s t test (*n* = 5 independent experiments).Also see [Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C and [S3](#mmc1){ref-type="supplementary-material"}A--S3C.

To further investigate the mitochondrial bioenergetic deficit in SOD1^G93A^ mice, we assessed respiration states of mitochondria isolated from skeletal muscle and spinal cord of SOD1^G93A^ mice and wild-type litter matched controls. We observed a decrease in maximally coupled respiration (state 2), thereby confirming the impairment in ATP production. Moreover, maximal respiration (state 4), determined through the addition of the uncoupling agent FCCP, appeared to be significantly compromised in mitochondria obtained from glycolytic TA, GNM, and EDL of presymptomatic SOD1^G93A^ mice ([Figures 3](#fig3){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Interestingly, mitochondria purified from a purely oxidative muscle, the *soleus*, were not affected ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). With the aim of characterizing the alterations in the electron transport chain, we performed a spectrophotometric analysis of the functional activities of the mitochondrial complexes and observed a specific impairment in Complex I in mitochondria purified from the TA ([Figure 3](#fig3){ref-type="fig"}D) and GNM (not shown) of early presymptomatic SOD1^G93A^ mice. Again, this dysfunction was evident in skeletal muscle from early presymptomatic SOD1^G93A^ mice, whereas defects in Complex I activity were only observed in the spinal cords of SOD1^G93A^ mice at the symptomatic and end stage of disease ([Figure 3](#fig3){ref-type="fig"}E).

Next, we performed Blue Native polyacrylamide gel electrophoresis (BN-PAGE) analysis of digitonin-extracted mitochondrial membranes obtained from the TA of SOD1^G93A^ mice and their wild-type control littermates at different ages ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We found no difference in the assembly of electron transport chain complexes or supercomplexes in mitochondria obtained from SOD1^G93A^ mice when compared with age-matched controls. Finally, bioenergetic assessment of primary cultures of skeletal muscle satellite cells isolated from early presymptomatic SOD1^G93A^ mice (55 days of age) revealed significant decreases in basal respiration, ATP production, maximal respiration, and spare respiratory capacity when compared with those isolated from their wild-type control littermates ([Figures 4](#fig4){ref-type="fig"}A and 4B). The decline in maximal respiration and spare respiratory capacity suggests that ALS may inhibit the rapid adaptation of skeletal muscle satellite cells to metabolic changes. Thus, although the number of mitochondria in the whole muscle appears to increase in SOD1^G93A^ mice, mitochondrial metabolism is compromised early in the course of the disease, leading to ATP deficit and impairments in OXPHOS functionality.Figure 4Mitochondrial Bioenergetics Failure Occurs in Skeletal Muscle Satellite Cells Isolated from Early Presymptomatic SOD1^G93A^ Mice(A) Representative trace of oxygen consumption rate (OCR) in skeletal muscle satellite cells isolated from early presymptomatic SOD1^G93A^ mice (55 days) and their wild-type control littermates (WT).(B) Individual parameters obtained for basal respiration, ATP production, maximal respiration, and spare respiratory capacity. Each data point represents an OCR measurement. Data are presented as mean ± SEM, ∗∗p \< 0.001, ∗∗∗p \< 0.0001 relative to WT control, p values obtained from unpaired Student\'s t test. Data from four independent experiments, with each sample tested in quadruplicate.

Muscle Mitochondrial Deficit in SOD1^G93A^ Mice Occurs in Parallel with an Activation of Molecular Pathways that Compensate for Energy Failure {#sec2.4}
----------------------------------------------------------------------------------------------------------------------------------------------

In normal physiology, a decrease in ATP production (mitochondrial alterations) leads to an enhancement in AMPK activity to promote the binding of AMP (and ADP) to the kinase subunit. This in turn induces the phosphorylation of a wide range of downstream proteins that eventually lead to the activation of catabolic pathways ([@bib21]). In particular, pharmacological or genetic inhibition of Complex I is sufficient to activate AMPK ([@bib21], [@bib51]). Therefore, in light of the bioenergetic defects observed in early presymptomatic mice and the specific impairment of Complex I activity, we analyzed the extent of AMPK activation in ALS mice.

Glycolytic skeletal muscles from SOD1^G93A^ mice displayed a robust activation of AMPK, long before the appearance of locomotor symptoms ([Figures 5](#fig5){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}). AMPK activation occurred in parallel with the phosphorylation/inactivation of the AMPK downstream target Acetyl-CoA Carboxylase (ACC), which catalyzes the first step of fatty acid synthesis ([Figures 5](#fig5){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}). Moreover, we found an upregulation in carnitine palmitoyltransferase 1 (CPT1) in the skeletal muscle of presymptomatic SOD1^G93A^ mice ([Figures 5](#fig5){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}). Finally, in support of a metabolic shift toward lipid use, we observed a decrease in the expression of Glucose Transporter type 4 (Glut4) mRNA and the concomitant increase in pyruvate dehydrogenase kinase 4 (Pdk4) mRNA in skeletal muscle of presymptomatic mice ([Figure 5](#fig5){ref-type="fig"}B).Figure 5Alterations in Expression of Metabolic Targets Occurs Early in the *tibialis anterior (TA)* of SOD1^G93A^ Mice(A) Representative western blot images of pAMPK, AMPK, pACC, ACC, and CPT1 (upper panel) in the TA of SOD1^G93A^ and wild-type mice at 55 days of age. GAPDH was used as loading control. Densitometric analysis of pAMPK/AMPK and pACC/ACC ratios and CPT1 expression (lower panel) from *n* = 4 independent experiments.(B) Expression of mRNAs coding for Pdk4 and Glut4 in the TA of SOD1^G93A^ mice relative to wild-type litter-matched controls. Data presented as mean ± SEM, ∗p \< 0.05, ∗∗p \< 0.001, ∗∗∗p \< 0.0001 when compared with control littermates at the same age (arbitrarily set at 1), unpaired Student\'s t test.Also see [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}A--S5C.

Sarcolipin Is an Early Player in ALS Metabolic Alterations {#sec2.5}
----------------------------------------------------------

Recent studies have outlined the pivotal role of sarcolipin (SLN) in orchestrating the transition toward oxidative metabolism in skeletal muscle ([@bib32]). In line with the literature ([@bib2]), we found that SLN is highly expressed in the TA of wild-type control mice until 14 days of age, after which it gradually declines ([Figure 6](#fig6){ref-type="fig"}A). By contrast, in SOD1^G93A^ mice, the expression level of SLN remained detectable in TA beyond 14 days of age, increasing during the course of the disease ([Figure 6](#fig6){ref-type="fig"}A). Indeed, in SOD1^G93A^ mice, SLN overexpression was strongly upregulated through to the end stage of disease in all glycolytic and oxidative muscles assessed. This is in contrast to the expression profile of SLN in age-matched wild-type control mice, where SLN was only detectable in the oxidative *soleus* ([Figure 6](#fig6){ref-type="fig"}B). Of note, we did not observe any significant variation in mRNA expression of phospholamban (PLN) or myoregulin (MLN) ([Figure S5](#mmc1){ref-type="supplementary-material"}A), muscular micropeptides that function similarly to SLN. Thus, our data suggest that SLN is the only SERCA-regulatory micropeptide involved in ALS.Figure 6Upregulation of Sarcolipin in ALS Occurs before Denervation in SOD1^G93A^ Mice(A and B) Representative western blots of sarcolipin (SLN) protein expression in the (A) tibialis anterior (TA) or (B) Extensor *digitorum longus* (EDL), *gastrocnemius* (GNM), and *soleus* muscle of SOD1^G93A^ (+) and wild-type mice (−) at the indicated ages.(C) Western blot of pCaMKII and CaMKII in the TA of SOD1^G93A^ (+) and wild type mice (−) at the indicated ages; GAPDH was used as loading control in (A--C).(D) SLN protein expression in different muscle biopsies derived from MELAS, neuropathy (N), not Limb Girdle Muscle Dystrophy (LGMD) and patients with ALS (1 = SOD1^D90A^ mutation, *soleus*; 2 = sporadic, *vastus lateralis*; 3 = Valosin Containing Protein (VCP) mutation, *vastus lateralis*; 4 = *C9ORF72* repeat expansions, *soleus*; 5 = sporadic, *vastus lateralis*; 6 = sporadic, *rectus femoralis*).(E) Densitometric analysis of (D) normalized to GAPDH protein expression. Data are presented as a percentage, where an arbitrary value of 100% was assigned to patients with ALS, ∗∗∗p \< 0.0001, one-way parametric ANOVA and Tukey\'s post hoc test.(F) Expression of mRNAs coding for Sarcolipin (Sln), Acetylcholine Receptor α subunit (Achrα), Acetylcholine Receptor ϵ subunit (Achrϵ), Voltage-gated Na channels 1.5 (Nav1.5), Histone Deacetylase 4 (Hdac4), Myogenin, MuscleRING Finger-1 (Murf1), and Myostatin in the TA of SOD1^G93A^ mice relative to their wild-type control littermates, ∗p \< 0.05, ∗∗p \< 0.001 ∗∗∗p \< 0.0001 when compared with age control littermates (arbitrarily set at 1).(G) Expression of mRNAs coding for Sln and denervation markers (Achrα, Nav1.5, Hdac4, and Myogenin) in the TA of wild-type mice 3 and 15 days after sciatic nerve axotomy. Data are expressed as the ratio between the average of values from not axotomized and axotomized mice, ∗p \< 0.05, ∗∗p \< 0.001 when compared with control not axotomized mice (arbitrarily set on at 1), and ^\#\#^p \< 0.001 between mice after 3 and 15 days from axotomy. All data are presented as mean ± SEM, unpaired Student\'s t test (E) and parametric ANOVA and a Bonferroni post hoc test (F), *n* = 3 or 4 independent experiments.See also [Table 1](#tbl1){ref-type="table"}.

An upregulation in SLN is known to trigger an increase in cytosolic calcium concentration in skeletal muscle ([@bib31]). To this end, we found a significant activation of Ca^2+^/calmodulin-dependent protein kinase II (CaMKII) in skeletal muscle of SOD1^G93A^ at the presymptomatic stage of the disease, when the glycolytic muscle was highly oxidative ([Figure 6](#fig6){ref-type="fig"}C). Moreover, we observed a significant increase in PGC-1α protein expression in the TA of SOD1^G93A^ mice at the presymptomatic phase of disease (70 days of age) as well as throughout the course of the disease ([Figure S5](#mmc1){ref-type="supplementary-material"}B).

The expression pattern of mRNAs coding for different isoforms of SERCA pumps reflects the metabolic profile of muscle. SERCA2a and SERCA2b isoforms that are normally associated with oxidative muscle, were more highly expressed in the TA from SOD1^G93A^ mice, whereas the glycolytic muscle-associated SERCA1 isoform was downregulated at the presymptomatic stage ([Figure S5](#mmc1){ref-type="supplementary-material"}C). It is noteworthy that SLN selectively binds SERCA2 isoforms, interacting with these to trigger the transition of skeletal muscle from glycolytic to oxidative metabolism ([@bib1]). Finally, highly relevant was the finding that SLN expression was upregulated in muscle biopsies obtained from six patients affected by different forms of ALS (for details see [Table 1](#tbl1){ref-type="table"}). Indeed, all ALS biopsies showed higher expression levels of SLN when compared with control patients affected by other muscular disorders ([Figures 6](#fig6){ref-type="fig"}D and 6E).Table 1Demographics of Patients with ALSPatientAge (years)SexALS MutationMonths from DiagnosisMuscle (Biopsies Were Done on Limb Muscle where the Disease Began)Patient Information147FSOD1^D90A^12*soleus dx*Spinal onset272FSporadic42*vastus lateralis dx*Spinal onset350MVCP mutation54*vastus lateralis dx*Spinal onset with IBM (inclusion body myositis) and Paget\'s disease462FC9ORF72 (58 repeats)33*soleus dx*Spinal onset with progressive muscle atrophy577FSporadic19*vastus lateralis dx*Spinal onset671FSporadic14*rectus femoris dx*N/A

Sarcolipin Overexpression in SOD1^G93A^ Mice Is Not Related to Muscle Denervation {#sec2.6}
---------------------------------------------------------------------------------

Several pathological conditions that lead to skeletal muscle disuse and subsequent atrophy affect not only muscle mass but also muscle metabolism ([@bib52]). SLN has been described to be a key mediator of metabolic modifications occurring in unloaded/disused muscle ([@bib14]). Thus, to discriminate whether SLN upregulation is causally linked to the altered metabolic state observed in ALS mice, or whether it is merely a consequence of early denervation, we analyzed the expression levels of several denervation/atrophy markers. Our results demonstrate that, in TA from SOD1^G93A^ mice, SLN is upregulated at the early presymptomatic stage, whereas mRNAs coding for Hdac4, Nav1.5, Myogenin, AchRε, AchRα, Murf1, and Myostatin, all associated with the denervation process, are only increased at the later stages of disease ([Figure 6](#fig6){ref-type="fig"}F).

In order to further decipher the relationship between denervation and metabolic alterations in skeletal muscle from ALS mice, we used an experimental paradigm of acute denervation. As shown in [Figure 6](#fig6){ref-type="fig"}G, sciatic nerve axotomy in control mice evoked an upregulation in denervation markers after 3 days, whereas SLN was only found to increase after 15 days. Overall, our data strongly suggest that, in ALS, muscle metabolic reprogramming is orchestrated by SLN and this occurs independent of denervation.

Altered Muscle Performance in SOD1^G93A^ Mice Is Related to Hypermetabolism {#sec2.7}
---------------------------------------------------------------------------

Given the altered bioenergetic profiles observed in SOD1^G93A^ mice, we next tested whether pharmacological targeting of altered energy metabolism could be a beneficial therapeutic approach in ALS. To address this aim, we chronically administered ranolazine (RAN) to SOD1^G93A^ mice. RAN is a US Food and Drug Administration (FDA)-approved drug that is used to treat ventricular hypertrophy, and it has been shown to exert cardioprotective effects by facilitating higher energy production under conditions of lower oxygen supply ([@bib49]). This drug decreases β-oxidation, thereby restoring the use of glucose as fuel ([@bib33]).

In a preliminary dose-response study, a small cohort of SOD1^G93A^ mice and age-matched wild-type control mice received daily intraperitoneal (i.p.) injections, for seven consecutive days, of three different doses of RAN (25, 50, 100 mg/kg). Treatment commenced at an age that corresponds to the symptomatic stage of the disease in SOD1^G93A^ mice (110 days). Bioavailability of RAN in plasma was assessed by high-performance liquid chromatography (HPLC), and results confirmed a dose-dependent increase ([Table 2](#tbl2){ref-type="table"}). RAN concentration values were consistent with those registered in more extended pharmacokinetics and pharmacodynamics studies reported by others ([@bib40]). Analysis of grip strength and SLN expression were used as readouts to determine the efficacy of RAN treatment. Strikingly, SOD1^G93A^ mice receiving 50 and 100 mg/kg of RAN showed a marked increase in muscular strength after 2 days of treatment. This improvement was maintained throughout the 7-day treatment period ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Similar results were obtained with a lower dose of RAN (25 mg/kg), which showed a significant, although delayed, efficacy. Furthermore, in the TA muscle of SOD1^G93A^ mice, SLN expression was reduced after 7 days of treatment. This was most evident at a RAN dose of 50 mg/kg ([Figure S6](#mmc1){ref-type="supplementary-material"}B). As such, 50 mg/kg of RAN was selected as the most effective dose.Table 2HPLC Determination of Ranolazine (RAN) Plasma Concentrations 12 h after i.p. Administration of Ranolazine at 25, 50, or 100 mg/kgRAN Dose (mg/kg)WT (μM)SOD1^G93A^ (μM)250.63 ± 0.160.79 ± 0.11501.22 ± 0.201.30 ± 0.181003.33 ± 0.212.87 ± 0.17[^3]

A second, larger cohort of SOD1^G93A^ mice received 50 mg/kg RAN from the onset stage of disease (90 days) through the end stage of disease. As shown in [Figure 7](#fig7){ref-type="fig"}A, RAN treatment improved hanging grid performance in SOD1^G93A^ mice up until the fully symptomatic stage of the disease (132 days). However, this improvement was not sustained; hanging grid performance in RAN-treated SOD1^G93A^ mice was comparable with that of non-treated SOD1^G93A^ mice by the end stage of disease ([Figure 7](#fig7){ref-type="fig"}A). Interestingly, RAN exerted similar effects on wild-type mice ([Figure S7](#mmc1){ref-type="supplementary-material"}). Despite improving hanging grid performance in SOD1^G93A^ mice, RAN failed to improve survival ([Figure 7](#fig7){ref-type="fig"}B) and it did not provide weight changes (data not shown). Interestingly, RAN treatment improves glycemia and reverses glucose intolerance in murine models of metabolic alterations without modifying body weight development ([@bib4], [@bib37]).Figure 7Ranolazine Improves Locomotor Abilities but Does Not Affect Survival(A) Locomotor abilities of SOD1^G93A^ mice receiving daily intraperitoneal injections of Ranolazine 50 mg/kg (SOD1^G93A^ RAN) or physiological solution (SOD1^G93A^) evaluated by hanging grid test at the indicated days. Performance was evaluated from 90 days of age (start of treatment) to the end stage of disease. Data are presented as mean ± SEM, ∗p \< 0.05 ∗∗p \< 0.001 ∗∗∗p \< 0.0001 when compared with age-matched SOD1^G93A^ untreated mice, and ^\#^p \< 0.05 ^\#\#^p \< 0.01 ^\#\#\#^p \< 0.0001 when compared with SOD1^G93A^ mice at the beginning of treatment. (*n* = 12 SOD1^G93A^, *n* = 12 SOD1^G93A^ + RAN).(B) Kaplan-Meier survival curve of SOD1^G93A^ mice and their wild-type control littermates (WT) receiving daily intraperitoneal injections of Ranolazine 50 mg/kg (SOD1^G93A^ RAN and WT RAN) or physiological solution (SOD1^G93A^ and WT). p Values were obtained using parametric two-way ANOVA with Bonferroni post hoc test (A) or one-way ANOVA with Bonferroni post hoc test (B).Also [Figure S7](#mmc1){ref-type="supplementary-material"}.

It is noteworthy that treatment efficacy followed the trend of expression/activation of muscle metabolic markers. Indeed, after 30 days of treatment with RAN, SLN was markedly downregulated and CaMKII and AMPK were inactivated by dephosphorylation, whereas the AMPK target, ACC, was dephosphorylated and hence reactivated ([Figures 8](#fig8){ref-type="fig"}A and 8B). Similarly, expression levels of mRNAs encoding myosin subtypes and SERCA pumps were decreased in response to RAN ([Figure 8](#fig8){ref-type="fig"}C), whereas mRNAs encoding Nor1 and Glut4 returned to levels similar to that observed in wild-type control mice ([Figure 8](#fig8){ref-type="fig"}C). In line with RAN\'s known mechanism of action in improving glucose metabolism, fluorometric determination of total ATP content showed a net increase in ATP concentration in the TA from symptomatic, 120-day-old SOD1^G93A^ mice when compared with their wild-type control littermates ([Figure 8](#fig8){ref-type="fig"}D).Figure 8Chronic Ranolazine (RAN) Administration Restores Metabolic HomeostasisMid-term evaluation (120 days) of SOD1^G93A^ mice receiving daily RAN (50 mg/kg i.p.) from 90 days of age.(A) Western blot analysis of SLN, pCaMKII, CaMKII, pAMPK, AMPK, pACC, and ACC in the tibialis anterior (TA) of SOD1^G93A^ mice (+) and wild-type control littermates (−) receiving daily RAN (+) or vehicle (−) at 120 days of age. GAPDH was used as loading control.(B) Densitometric analysis of data obtained in (A). Data are presented as mean ± SEM, ∗p \< 0.05, ∗∗p \< 0.001 when compared with wild-type untreated mice (arbitrarily set on at 1) and ^\#^p \< 0.05 ^\#\#^p \< 0.001 when compared with SOD1^G93A^ untreated mice (*n* = 6 independent experiments), parametric one-way ANOVA and a Bonferroni post hoc test.(C) Expression of mRNAs coding for Nor1, Glut4, Serca1, Serca2a, Serca2b, MyHCI, MyHCIIa, MyHCIIx, MyHCIIb in the TA of SOD1^G93A^ mice and wild-type control littermates treated with RAN (SOD1^G93A,^ RAN and WT RAN) or not treated with RAN (SOD1^G93A^ and WT) at 120 days of age (*n* = 4 for each genotype/treatment). Data are presented as mean ± SEM, ∗∗p \< 0.001 when compared with wild-type untreated mice (arbitrarily set on at 1) and ^\#^p \< 0.05 when compared with SOD1^G93A^ untreated mice (*n* = 6 independent experiments), parametric one-way ANOVA and a Bonferroni post hoc test.(D) Fluorometric measurement of total ATP in the TA of SOD1^G93A^ mice and wild-type control littermates receiving daily RAN (+) or vehicle (−) at 120 days of age. Data were analyzed by one-way ANOVA with multiple comparisons using Dunnet\'s t test and Tukey\'s HSD (Honestly Significantly Different) post hoc test. Data presented as mean ± SEM, ∗∗∗p \< 0.0001 when compared with WT untreated mice and ^\#\#^p \< 0.001 when compared with SOD1^G93A^ untreated mice (*n* = 4 independent experiments).(E) Energy expenditure profile (EE) of WT and SOD1^G93A^ treated with RAN or vehicle at 120 days of age. Black bar indicates the dark cycle period.(F--H) (F) Percentage of increase in EE between 55 and 120days of age, and effects of RAN treatment (initiation of treatment marked with an arrow) from day 90 onward. Mean of (G) EE and (H) Resting EE (REE) obtained from WT and SOD1^G93A^ mice in (E). Data are presented as mean ± SEM, ∗∗∗p \< 0.0001 when compared with WT mice; ^\#\#\#^p \< 0.0001 when compared with SOD1^G93A^ mice (at least *n* = 4 animals), two-way ANOVA with Tukey post hoc test.(I--K) (I) Respiratory exchange ratio (RER) demonstrating the extent of lipid versus carbohydrate oxidation. Data are presented as mean ± SEM, ∗∗∗p \< 0.0001 when compared with WT mice; (at least *n* = 4 animals), two-way ANOVA with Tukey post hoc test. Long-term evaluation (150 days) of RAN treatment started at 90 days of age: (J) western blot analysis of SLN, pCaMKII, CaMKII, pAMPK, AMPK, pACC, and ACC in the TA of SOD1^G93A^ (+) and wild-type (−) RAN-treated (+) or untreated (−) mice. GAPDH was used as loading control. (K) Densitometric analysis of data in (I). Data are presented as mean ± SEM, ∗∗p \< 0.001 when compared with WT untreated mice (arbitrarily set on at 1) and ^\#^p \< 0.05 when compared with SOD1^G93A^ untreated (*n* = 6 independent experiments), parametric one-way ANOVA and a Bonferroni post hoc test.

Given that progressive changes in muscle metabolic markers in SOD1^G93A^ mice occurred alongside the presentation of hypermetabolism, we next aimed to determine whether RAN would attenuate hypermetabolism in SOD1^G93A^ mice. Indeed, indirect calorimetry analysis showed that hypermetabolism was partially abrogated after treatment with RAN ([Figures 8](#fig8){ref-type="fig"}E and 8F). RAN restored EE ([Figure 8](#fig8){ref-type="fig"}G) and REE ([Figure 8](#fig8){ref-type="fig"}H) but had no effect on RER ([Figure 8](#fig8){ref-type="fig"}I). Surprisingly, the weakening of RAN effects during the end stage of the disease was paralleled with an increase in the expression of SLN, the reactivation of CaMKII and AMPK, and thus ACC inactivation ([Figures 8](#fig8){ref-type="fig"}, 8J, and 8K). Overall, these results show that decreasing EE is linked to an improvement in grip strength in SOD1^G93A^ mice. Our data highlight the potential relevance of pharmacological interventions aimed at counteracting hypermetabolism in ALS.

Discussion {#sec3}
==========

In this study, we detail the existence of early events responsible for the remodeling of myofiber-type composition and defective energy metabolism in the SOD1^G93A^ mouse model of ALS. Our observations are in agreement with previous work demonstrating a shift in fast-to-slow muscle fiber type composition ([@bib42]), as well as aberrant mitochondrial metabolism ([@bib46]) and alterations in muscle glucose metabolism in response to muscle-restricted overexpression of SOD1^G93A^ ([@bib10], [@bib11]). Moreover, in line with the derangement in whole-body EE that we identified in symptomatic SOD1^G93A^ mice, hypermetabolism has been described in many patients with ALS ([@bib6], [@bib9], [@bib16], [@bib27], [@bib50]) and often associated with dyslipidemia ([@bib13]). Notably, prognosis is less favorable in hypermetabolic patients ([@bib50]), whereas dyslipidemia/hyperlipidemia may confer protection and increase survival ([@bib13]).

Given that skeletal muscle is a major determinant of whole-body energy metabolism ([@bib58]), we focused our investigation on the contribution of skeletal muscle to SOD1^G93A^ metabolic dysfunction. Indeed, we found some prodromal molecular signatures of oxidative metabolism at 55 days of age, including an initial increase in NADH-TR and SDH activities and an increase in mitochondrial mass in fast-twitch glycolytic muscles. Thus, we identified a fast-to-slow skeletal muscle fiber transition in the early presymptomatic stage; this pathological rearrangement of muscle phenotype might partially account for the marked increase of fatty acid β-oxidation observed before disease onset. However, according to previous evidence ([@bib12]), hypermetabolism occurs in SOD1 G93A mice only at a symptomatic stage of the disease, whereas it is undetectable at 55 days of age. It should be considered that, around 55 days of postnatal life, the skeletal muscle of SOD1 G93A mice are not yet fully oxidative.

Skeletal muscle is a dynamic tissue that is highly adaptable to environmental changes and to alterations in energy need. Physical exercise is a key modulator of muscle plasticity, as enduring contractile activity, it is a powerful stimulus for enhancing mitochondrial biogenesis ([@bib23]). This condition upregulates mitochondrial enzymes involved in fatty acid β-oxidation ([@bib30]) to promote myofiber switching from fast (glycolytic) to slow (oxidative) fiber types ([@bib15]). In this view, the muscle alterations that we have observed in SOD1^G93A^ mice appear to mimic a state of long-lasting endurance exercise. Indeed, Palamiuc et al. ([@bib39]) have previously reported increased endurance capacity in SOD1^G86R^ mice at an advanced phase of disease. Although it remains unknown as to why there is a shift in muscle fiber type, and enhanced fatty acid utilization in the absence of environmental pressure and/or physical exercise in SOD1^G93A^ mice, this exercise-mimetic phenotype may be associated with aberrant energy needs that may be associated with early mitochondrial dysfunction and/or SLN overexpression.

Mitochondrial Dysfunction {#sec3.1}
-------------------------

In light of the critical role that mitochondria play in muscle metabolism and plasticity, it is conceivable that early alterations in muscle mitochondria might contribute to altered energy homeostasis in ALS. In agreement with this hypothesis, we report mitochondrial impairments in skeletal muscle in early presymptomatic SOD1^G93A^ mice, which occur prior to the presentation of motor symptoms. Recently, an association between myopathy and defective mitochondrial function has been described in a different ALS mouse model ([@bib17]), thus underlining the importance of muscle bioenergetics in neuron motor disease. In line with premature atrophy and loss of function of fast-twitch fibers ([@bib22], [@bib39], [@bib42]), we detected early mitochondrial metabolic alterations in glycolytic EDL, TA, and GNM but not in oxidative *soleus*. Interestingly, skeletal muscle satellite cells isolated from early presymptomatic SOD1^G93A^ mice also exhibited defective bioenergetic profiles. The drop in energy production in these skeletal muscle stem cells and their inability to respond to metabolic changes might affect muscle regeneration in response to denervation as previously described in ALS pathology ([@bib53], [@bib57]).

We found an early impairment of Complex I activity in skeletal muscle of SOD1^G93A^ mice. An impairment of Complex I activity has previously been described in muscle biopsies from patients with sporadic ALS ([@bib56]). Moreover, functional alterations of the Complex I has been observed in GNM isolated from SOD1^G93A^ mice at 7 weeks of age ([@bib8]). Collectively, these observations corroborate the hypothesis that, in patients with ALS ([@bib18]) and in preclinical models ([@bib47], [@bib54]), Complex I activity is a selective target of different ALS-related proteins. Complex I can be considered as an energy-transducing enzyme whose activity regulates cell energy request and activates catabolic pathways following the failure of its activity ([@bib25], [@bib29]). Accordingly, pharmacological inhibition or a failure in Complex I activity triggers the activation of the AMPK ([@bib24], [@bib25]). AMPK activation promotes catabolic pathways, such as lipid oxidation in skeletal muscle ([@bib35], [@bib38]). This known action of AMPK is in line with the increase in lipid oxidation and inhibition of glucose utilization that we observed here in early presymptomatic mice. In the context of ALS, mitochondrial failure could drive an increase in the use of lipids as primary fuel substrate to compensate for energy deficit and a decline in ATP synthesis. Subsequent to this, excess ROS generation as a result of excessive mitochondrial lipid oxidation may further aggravate mitochondrial dysfunction ([@bib43], [@bib44]).

SLN Overexpression {#sec3.2}
------------------

SLN is a micropeptide inhibitor of SERCA activity that uncouples Ca^2+^ transport from ATP hydrolysis ([@bib3], [@bib48]). Thus, SLN has a critical role in determining metabolic rate, EE, and muscle-derived thermogenesis ([@bib3], [@bib31], [@bib32]). Notably, selective SLN overexpression in fast-twitch glycolytic muscle has been shown to reprogram mitochondria and induce an oxidative phenotype ([@bib32]). The expression of SLN is tightly regulated during development, and in rodents, its expression is detectable in skeletal muscle during late embryonic development and early neonatal life ([@bib2]). Accordingly, in control mice SLN expression was downregulated in glycolytic muscle by postnatal day 15, whereas its expression was highly upregulated in the same muscle during the entire life course of SOD1^G93A^ mice. More interestingly, we found marked SLN overexpression in muscle biopsies from patients affected by genetic and sporadic forms of ALS. Although SLN has already been viewed as a feasible prognostic or early diagnostic biomarker in ALS, its upregulation has been associated with disease-specific denervation ([@bib7]) rather than specific metabolic signatures. In contrast to this, our results indicate that SLN is overexpressed before the upregulation of any denervation markers. Although our data do not pinpoint SLN upregulation as being the primary "source" of hypermetabolism in ALS, early mitochondrial failure and energy deficit could underlie SLN overexpression and activate compensatory oxidative metabolism. Indeed, SLN plays a central role in the adaptive mechanisms that couple increased energy request (e.g., diet-induced obesity), cold acclimatization, and exercise with mitochondrial ATP and energy production ([@bib32]). Thus, the increase of SLN expression in ALS might represent a classical adaptation to increased energy demand, leading to a shift in substrate utilization, mitochondrial biogenesis, and oxidative metabolism in glycolytic muscle.

RAN Treatment {#sec3.3}
-------------

To determine whether decreasing energy demand and re-balancing substrate utilization might be of benefit in ALS, we aimed to assess the potential therapeutic role of RAN, an FDA-approved fatty acid oxidation inhibitor that is used for the management of cardiac dysfunction ([@bib5], [@bib49]). We demonstrate that chronic RAN treatment in SOD1^G93A^ mice significantly improves motor function in SOD1^G93A^ by slowing the decline in muscle strength over a 6-week treatment period. Moreover, during mid-term treatment evaluation (120 days of age), we found that RAN attenuated excessive whole-body EE in SOD1^G93A^ mice, and although it did not offset increased fatty acid β-oxidation, RAN treatment improved energy metabolism by increasing muscle ATP content.

Interestingly, we found that, by the end stage of disease (at 150 days), RAN had lost its efficacy and there was a re-emergence of hypermetabolism. It should be noted that, in patients with stable angina pectoris, the recommended posology includes the escalation of drug dosage during therapy ([www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000805/human_med_001009.jsp&mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000805/human_med_001009.jsp&mid=WC0b01ac058001d124){#intref0010}). This suggests that the re-emergence of pathology at the end stage of disease in SOD1^G93A^ mice may be attributed to the loss of RAN efficacy rather than disease exacerbation. Of interest, RAN also acts as an inhibitor of late inward sodium currents (IpNa) during cardiac repolarization ([@bib59]). Hence, we cannot rule out that sodium channel facilitation of membrane repolarization might decrease cell energy demand to compensate for mitochondrial failure in skeletal muscle and neurons of SOD1^G93A^ mice.

Conclusions {#sec3.4}
-----------

Our study provides compelling evidence to demonstrate specific metabolic dysfunction and mitochondrial failure as early pathophysiological events in ALS. Here, we may consider that a slight drop in ATP production via mitochondrial impairment or SLN overexpression may become pathologically relevant when energy demand increases as a result of lifestyle changes or during aging. In this scenario, a timely pharmacological intervention impinging on hypermetabolism may be a promising therapeutic option to improve quality of life.

Limitations of the Study {#sec3.5}
------------------------

In this study we use an FDA-approved drug, Ranolazine, to counteract hypermetabolism in an ALS mouse model. In our hands, Ranolazine ameliorates locomotor symptoms of fully symptomatic ALS mice, but its effect is temporary. In this regard, RAN does not improve life span in SOD1^G93A^ mice. Given that we have observed temporary restoration and recovery of metabolic indicators, the loss of effectiveness of Ranolazine requires further investigation through extended pharmacokinetics and pharmacodynamics studies. From our study, we provide proof of concept that hypermetabolism appears to be considered a viable therapeutic target in ALS. As such, alternate drugs that are known to modulate metabolism should also be considered.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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